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Plasma non-transferrin-bound iron (NTBI)
is amain contributor to tissue iron loading
in iron overload disorders such as
hereditary hemochromatosis.
Jenkitkasemwong et al. show that loss of
the metal-ion transporter SLC39A14
impairs NTBI uptake by the liver and
prevents hepatic iron overload in mouse
models of hemochromatosis.
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Nearly all forms of hereditary hemochromatosis are
characterized by pathological iron accumulation in
the liver, pancreas, and heart. These tissues prefer-
entially load iron because they take up non-trans-
ferrin-bound iron (NTBI), which appears in the
plasma during iron overload. Yet, how tissues take
up NTBI is largely unknown. We report that ablation
of Slc39a14, the gene coding for solute carrier
SLC39A14 (also called ZIP14), in mice markedly
reduced the uptake of plasma NTBI by the liver and
pancreas. To test the role of SLC39A14 in tissue
iron loading, we crossed Slc39a14/ mice with
Hfe/ and Hfe2/ mice, animal models of type 1
and type 2 (juvenile) hemochromatosis, respectively.
Slc39a14 deficiency in hemochromatotic mice
greatly diminished iron loading of the liver and pre-
vented iron deposition in hepatocytes and pancre-
atic acinar cells. The data suggest that inhibition of
SLC39A14 may mitigate hepatic and pancreatic iron
loading and associated pathologies in iron overload
disorders.
INTRODUCTION
Hereditary hemochromatosis is an autosomal recessive disorder
that results from increased intestinal iron absorption and subse-
quent iron accumulation in body tissues. More than 80% of
cases of hereditary hemochromatosis arise from a C282Y muta-
tion in the HFE gene (Feder et al., 1996). With a carrier frequency
of 1:200 to 1:300, the C282Y mutation is one of the most preva-
lent polymorphisms in individuals of northern European descent
(Merryweather-Clarke et al., 1997). InHFE-related (type 1) hemo-
chromatosis (OMIM 235200), iron absorption is increased
because of inadequate synthesis of hepcidin (Bridle et al.,138 Cell Metabolism 22, 138–150, July 7, 2015 ª2015 Elsevier Inc.2003), the iron-regulatory hormone that limits iron absorption
when body iron stores increase (Ganz and Nemeth, 2011).
Accordingly, mutations in other genes required for hepcidin syn-
thesis also lead to hereditary hemochromatosis. These genes
include HFE2, commonly known as hemojuvelin (Papanikolaou
et al., 2004); HAMP, the hepcidin gene (Roetto et al., 2003);
and TFR2, transferrin receptor 2 (Camaschella et al., 2000). Mu-
tations in HFE2 and HAMP result in early-onset and severe iron
overload, clinically referred to as juvenile (type 2) hemochroma-
tosis (OMIM 602390). In hemochromatosis, iron loads primarily
in the liver starting with periportal hepatocytes (Pietrangelo,
2010). As the disease progresses, iron accumulates in the
remainder of the liver and also in the pancreas, where it deposits
predominantly in acinar cells (Rahier et al., 1987). Later in the dis-
ease, iron loads in the myocardium of the heart (Carpenter et al.,
2013). Clinical manifestations of hereditary hemochromatosis
include hepatic fibrosis, cirrhosis, diabetes, and cardiomyopathy
(Pietrangelo, 2010).
Hepcidin deficiency results in not only increased iron absorp-
tion but also increased iron release from reticuloendothelial mac-
rophages of the liver, spleen, and bone marrow that recycle iron
from senescent red blood cells (Knutson and Wessling-Resnick,
2003). Such unregulated iron entry into the plasma leads to
increased saturation of transferrin, the plasma protein that trans-
ports iron. High plasma transferrin saturations, typically >75% in
hereditary hemochromatosis, are associated with the presence
of a redox-active, chelatable pool of iron known as ‘‘non-trans-
ferrin-bound iron’’ (NTBI) (Le Lan et al., 2005). First described
in thalassemia major patients in 1978 (Hershko et al., 1978),
NTBI is now widely believed to be a major contributor to tissue
iron loading and related pathologies in iron overload disorders
(Brissot et al., 2012; Cabantchik, 2014; Fleming et al., 2005).
Studies in mice have demonstrated that NTBI in the plasma is
rapidly and efficiently taken upmostly by the liver and, to a lesser
extent, the pancreas, kidney, and heart (Bradbury et al., 1994;
Craven et al., 1987; Wang and Knutson, 2013).
Despite the importance of NTBI in the pathophysiology of iron
overload, the molecular mechanisms responsible for its tissue
uptake have remained elusive (Brissot et al., 2012). The most
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Figure 1. Hepatic and Pancreatic Uptake of
Intravenously Administered 59Fe-NTBI Is
Impaired in Slc39a14–/– Mice
(A) In vivo 59Fe-NTBI uptake by various tissues of
6-week-old wild-type (WT, n = 5) and Slc39a14/
mice (n = 10). Tissue uptake of 59Fe from NTBI was
calculated as a percentage of whole-body cpm.
(B) Immunoblot analysis of SLC39A14 in liver
homogenates from WT, Slc39a14+/, and
Slc39a14/ mice (n = 4 per group).
(C) In vivo 59Fe-NTBI uptake by the liver in WT
(n = 10), Slc39a14+/ (n = 9), and Slc39a14/
(n = 15) mice.
(D) In vitro 59Fe-NTBI uptake by cultures of primary
hepatocytes isolated from 13-week-old WT
and Slc39a14/ mice. Data are presented as
pmol 59Fe per mg of protein (n = 3 per group).
(E) In vivo 59Fe-TBI uptake by various tissues of
6-week-old WT and Slc39a14/mice (n = 4–5 per
group). Tissue uptake of 59Fe from TBI was
calculated as a percentage of whole-body cpm.
Data are presented as percent of total body cpm.
Significance was calculated by using Student’s
t test. All data are shown as themean ± SEM. ***p <
0.001, *p < 0.05.frequently proposed candidate for mediating NTBI uptake has
been divalent metal-ion transporter-1, DMT1 (SLC11A2), which
is required for intestinal uptake of dietary iron and iron uptake
by developing erythroid cells (Gunshin et al., 2005). We recently
tested the hypothesis that DMT1 plays a role in hepatic NTBI up-
take by using liver-specificDmt1 knockout mice and found that it
is dispensable for hepatic NTBI uptake and hepatocyte iron
loading (Wang and Knutson, 2013). A more recent candidate
for NTBI uptake is SLC39A14, a member of the ZIP family of
metal-ion transporters, which have mainly been characterized
by their ability to transport zinc (Taylor et al., 2005). In 2006,
we discovered that SLC39A14 could transport iron in addition
to zinc, and that it mediated NTBI uptake by cultured AML12
mouse hepatocytes (Liuzzi et al., 2006). Subsequently, we
demonstrated that SLC39A14 also mediated NTBI uptake in hu-
man hepatoma cells (Gao et al., 2008) and that the iron transport
properties of SLC39A14, when expressed in Xenopus laevis
oocytes, were consistent with studies of hepatic NTBI uptake
in vivo (Pinilla-Tenas et al., 2011). Among human tissues,
SLC39A14 is most abundantly expressed in liver, pancreas,
and heart (Nomura et al., 1994; Taylor et al., 2005; Wang et al.,
2012), suggesting that it may contribute to NTBI uptake and
iron accumulation by these tissues in iron overload disorders.Cell Metabolism 22, 138Consistent with a possible role for
SLC39A14 in NTBI uptake by the liver
and pancreas is our observation that
SLC39A14 protein levels are elevated
in iron-loaded liver and pancreas (Nam
et al., 2013). Here we formally tested
the role of SLC39A14 in tissue NTBI
uptake and iron loading by using
Slc39a14/ mice (Hojyo et al., 2011),
double-knockout Hfe/;Slc39a14/
and Hfe2/;Slc39a14/ mouse models
of hereditary hemochromatosis, and Slc39a14/ mice sub-
jected to dietary iron overload. We show that SLC39A14 is the
main NTBI transporter in the liver and pancreas, that it is essen-
tial for the development of hepatic iron overload in hemochroma-
tosis, and that it is required for iron loading of hepatocytes and
pancreatic acinar cells.
RESULTS
Ablation of Slc39a14 Impairs NTBI Uptake
To test the hypothesis that SLC39A14 plays a role in NTBI uptake
in vivo, we used Slc39a14/ mice and wild-type (WT) mice at
6 weeks of age. Mice were given an intravenous injection of ferric
citrate to transiently saturate plasma transferrin, followed by an
intravenous injection of 59Fe-labeled ferric citrate representing
NTBI. Two hours later, mice were sacrificed and tissues were
harvested for gamma counting. We found that 59Fe-NTBI uptake
was 70% lower in the liver and pancreas of Slc39a14/ mice
compared with WT mice (Figure 1A). By contrast, 59Fe-NTBI
uptake by the kidney, spleen, and carcass was higher in
Slc39a14/ mice compared with WT controls. Analysis of
hepatic 59Fe-NTBI uptake from heterozygous animals, which ex-
pressed 50% of WT SLC39A14 protein levels (Figure 1B),–150, July 7, 2015 ª2015 Elsevier Inc. 139
indicates that one allele of Slc39a14 is sufficient for normal
hepatic NTBI clearance (Figure 1C). Immunoblot analyses
confirmed the lack of SLC39A14 protein in Slc39a14/ mouse
liver (Figure 1B), pancreas, heart (Nam et al., 2013), and kidney
(data not shown). To investigate whether the impaired hepatic
NTBI uptake in Slc39a14/ mice is due to a defect in uptake
by hepatocytes, where SLC39A14 protein is most abundantly
expressed in the liver (Nam et al., 2013), we measured 59Fe-
NTBI uptake in isolated primary hepatocytes. Similar to the liver,
hepatocyte NTBI uptake from Slc39a14/ mice was markedly
impaired (Figure 1D).
We previously reported that SLC39A14 promotes the assimi-
lation of transferrin-bound iron (TBI) by cultured cells (Zhao
et al., 2010). Given that plasma TBI delivers iron to nearly all cells
and may contribute to iron loading of the liver (Trinder and Mor-
gan, 1997) and perhaps other tissues, we assessed whether tis-
sue uptake of TBI is affected in Slc39a14/mice. We found that
59Fe uptake from TBI was not altered in the liver, pancreas, heart,
kidney, and spleen of Slc39a14/ mice (Figure 1E), indicating
that SLC39A14 is dispensable for TBI uptake in these tissues.
Loss of Slc39a14 Prevents Hepatic Iron Overload in
Hemochromatosis
To determine whether SLC39A14 is required for tissue iron accu-
mulation in iron overload, we crossed Slc39a14/ mice with
Hfe/ mice, the animal model of HFE-related hereditary hemo-
chromatosis, to generate double-knockout Hfe/;Slc39a14/
mice. Similar to patients with the C282Y mutation in HFE,
Hfe/ mice hyperabsorb dietary iron and deposit it primarily in
the liver (Zhou et al., 1998). Accordingly, we found that Hfe/
mice at 4 weeks of age displayed elevated concentrations of
non-heme iron, an indicator of iron stores, in the liver, but not
the pancreas, heart, kidney, or spleen (Figure 2A). By contrast,
Hfe/;Slc39a14/ mice did not accumulate iron in the liver,
but did load iron in the kidney. The lack of hepatic iron accumu-
lation in Hfe/;Slc39a14/ mice was associated not with
impaired dietary iron absorption (Figure 2B) but instead with
impaired hepatic iron accumulation of absorbed iron (Figure 2C).
Although iron absorption did not differ significantly among
groups (Figure 2B), two-way ANOVA revealed a significant
main effect of genotype, with mice lacking Hfe having signifi-
cantly higher iron absorption (p < 0.05). Histochemical staining
for ferric iron deposits (Perls’ stain) in liver sections from Hfe/
mice revealed a periportal distribution of iron (Figure 2D), consis-
tent with previous studies (Fleming et al., 2001; Zhou et al.,
1998). In Hfe/;Slc39a14/ mice, negligible amounts of iron
were detectable by using Perls’ stain (Figure 2E) or themore sen-
sitive DAB-enhanced Perls’ stain (Figure 2F). Given that the liver
can take up iron from the plasma, wemeasured plasma iron con-
centrations, total iron-binding capacity (TIBC), transferrin satura-
tion, and plasma concentrations of NTBI (Figures 2G–2J).
Plasma iron indices were not significantly affected by loss of
Slc39a14, indicating that the lack of hepatic iron accumulation
in Hfe/;Slc39a14/ mice is not due to diminished levels of
plasma iron. As in our previous study (Hojyo et al., 2011), body
weights of 4-week-old Slc39a14/ mice were lower than those
of WT mice (Figure 2K). Body weights of Hfe/;Slc39a14/
mice tended to be lower than those of WT or Hfe/ mice, but
the difference was not statistically significant. Tissue nonheme140 Cell Metabolism 22, 138–150, July 7, 2015 ª2015 Elsevier Inc.iron concentrations were also assessed at 16 weeks of age
(see Figure S1D online). Similar to 4-week-old mice, 16-week-
old Hfe/;Slc39a14/ mice displayed a marked impairment
in hepatic iron accumulation and enhanced iron accumulation
in the kidney. In addition, nonheme iron concentrations in the
pancreas and heart were 60% and 24% higher, respectively, in
Hfe/;Slc39a14/ mice compared to Slc39a14/ animals.
To determine what effect a loss of Slc39a14 would have in a
more severe form of hemochromatosis, we generated double-
knockout Hfe2/;Slc39a14/ mice. Hfe2/ mice, the animal
model for juvenile hemochromatosis, develop rapid andmassive
iron overload, with iron depositing primarily in the liver and
secondarily in the pancreas and heart (Niederkofler et al.,
2005). Hfe2/ mice at 6 weeks of age exhibited elevated iron
content of the liver (15-fold), pancreas (17-fold), and
heart (1-fold) compared with WT controls (Figure 3A). Similar
to Hfe/;Slc39a14/ mice, double-knockout Hfe2/;
Slc39a14/mice displayed amarked impairment in iron loading
of the liver (Figure 3A). In addition, iron loading of the pancreas
was 60% less in Hfe2/;Slc39a14/ mice compared with
Hfe2/ controls. Interestingly, in comparison with Hfe2/
animals, Hfe2/;Slc39a14/ mice displayed 26% higher
nonheme iron concentrations in the heart and markedly elevated
iron concentrations in the kidney and spleen (2.6- and 11-fold,
respectively). These observations demonstrate that the heart,
kidney, and spleen have SLC39A14-independent pathways of
iron accumulation.
As expected, iron absorption was markedly elevated in
Hfe2/ mice (Figure 3B). Iron absorption was also elevated in
Hfe2/;Slc39a14/ mice compared to WT or Slc39a14/
animals but was 25% lower than in Hfe2/ mice. The lower
iron absorption inHfe2/;Slc39a14/mice was not associated
with differences in enterocyte protein levels of DMT1, the apical
iron importer, or ferroportin (FPN), the basolateral iron exporter
(Figure S2). Similar to Hfe/;Slc39a14/ mice (Figure 2C),
Hfe2/;Slc39a14/mice showed diminished hepatic accumu-
lation of absorbed iron compared with Hfe2/ animals (Fig-
ure 3C). A trend of enhanced uptake of absorbed iron into the
pancreas of Hfe2/;Slc39a14/ mice was observed, but it
did not reach statistical significance with this limited sample
size (n = 4) (Figure 3D). Consistent with previous findings (Nieder-
kofler et al., 2005), Hfe2/ mice displayed reduced concentra-
tions of iron in the spleen (Figure 3A), likely due to increased
iron release by reticuloendothelial macrophages of the red
pulp. Consequently, splenic accumulation of absorbed iron
was markedly lower in Hfe2/ mice compared to WT controls
(Figure 3E). By contrast, splenic accumulation of absorbed iron
was not lower in Hfe2/;Slc39a14/ mice (Figure 3E). Perls’
stain of liver sections revealed massive iron deposition
throughout hepatocytes of Hfe2/ mice, but no iron deposits
were detected in hepatocytes ofHfe2/;Slc39a14/mice (Fig-
ures 3F and 3G). By using DAB-enhanced Perls’ stain, however,
iron deposits became detectable in nonparenchymal cells of the
livers of Hfe2/;Slc39a14/ mice (Figure 3H). Costaining with
the macrophage marker F4/80 and Perls’ stain indicates that
some, but not all, of the iron was present in Kupffer cells (Fig-
ure S3A). Loss of Slc39a14 in the single- or double-knockout
mice did not affect TIBC, transferrin saturation, or plasma NTBI
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Figure 2. Ablation of Slc39a14 in Hfe–/– Mice Impairs Hepatic Iron Loading
(A) Tissue nonheme iron concentrations in WT, Slc39a14/, Hfe/, and Hfe/;Slc39a14/ mice at 4 weeks of age (n = 5–9 per group).
(B) Iron absorption (% of dose) was measured after intragastric gavage of 59Fe (n = 5–13 per group).
(C) Hepatic 59Fe accumulation (percent of absorbed 59Fe) was measured after intragastric gavage of 59Fe (n = 5–6 per group).
(D–F) Representative images of Perls’ iron stain in paraffin-embedded liver sections of mice at 4 weeks of age (n = 3 per group). Branches of the portal (P) and
central (C) veins are indicated. (D and E) Liver sections processed by using standard Perls’ iron stain (blue stain) and hematoxylin counterstain. Scale bars, 200
and 100 mm, respectively. (F) Serial liver sections processed by using DAB-enhanced Perls’ stain (black stain) and neutral red counterstain. Scale bars, 100 mm.
(G–J) Plasma iron indices. (G) Plasma iron concentrations (n = 5–6 per group). (H) Total iron-binding capacity, TIBC (n = 5–6 per group). (I) Transferrin saturation
(n = 5–6 per group). (J) Plasma NTBI concentrations (n = 8–13 per group).
(K) Body weights of mice at 4 weeks of age (n = 6–12 per group). All data are shown as the mean ± SEM. Means without a common superscript differ significantly
(p < 0.05). See also Figure S1.plasma NTBI concentrations relative to their respective controls
(Figure 3L). Body weights were lower in Hfe2/;Slc39a14/
mice than in Hfe2/ and Slc39a14/ controls (Figure 3M).
Older Hfe2/; Slc39a14/ mice (12 weeks of age) displayed
alterations in tissue nonheme iron concentrations that were
similar to those observed at 6 weeks of age (Figure S1E).Loss of Slc39a14 Alters Pancreatic Iron Accumulation
Given that the pancreas accumulates iron from NTBI (Craven
et al., 1987) and that Slc39a14/ mice showed impaired
pancreatic NTBI uptake (Figure 1A), we expected that
Slc39a14/ mice would display impaired iron loading of this
organ. Although we did find that pancreatic iron loading wasCell Metabolism 22, 138–150, July 7, 2015 ª2015 Elsevier Inc. 141
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impaired in Hfe2/;Slc39a14/ mice relative to Hfe2/ mice,
iron still accumulated to levels that were roughly ten times
normal (Figure 3A). In an effort to identify which cell types of
the pancreas accumulated iron, we used DAB-enhanced Perls’
stain, which was needed because Perls’ stain was not sensitive
enough to detect the low amounts of iron in this tissue at this age.
Serial pancreas sections were counterstained with neutral red
(+NR) to visualize tissue structures or processed without neutral
red (NR) to better see the iron deposits. Similar to a previous
report (Niederkofler et al., 2005), Hfe2/ mice accumulated
iron predominantly in pancreatic acinar cells, with little iron
detectable in islets (Figure 4A). However, in Hfe2/;
Slc39a14/mice, iron was not detected in acinar cells; instead,
strong staining was observed in inter- and perilobular regions
(Figure 4A). To identify which pancreatic structures were loading
iron, we analyzed serial tissue sections by using immunohisto-
chemistry and the protein markers PCK-26 for ductal epithelium,
CD-31 for blood vessel endothelium, LYVE-1 for lymphatic
endothelium, and collagen I for connective tissue. The iron stain-
ing overlapped best with collagen I (Figure 4B), suggesting that
iron is depositing in connective tissue in the pancreas
ofHfe2/;Slc39a14/mice. Iron loading in pancreatic connec-
tive tissue has been reported previously (Giorgi and Roque,
2014). The altered pattern of pancreatic iron deposition in
Hfe2/;Slc39a14/ mice is readily observed by Perls’ staining
of pancreas sections from 12-week-old mice (Figure S4A).Loss of Slc39a14 in Dietary Iron Overload
The data from theHfe/;Slc39a14/ and Hfe2/;Slc39a14/
mice show that Slc39a14 is required for the development of he-
patic iron overload in mousemodels of hemochromatosis. Given
that the loss of Hfe and Hfe2 results in hemochromatosis by im-
pairing hepcidin expression, we next sought to examine what ef-
fect the loss of Slc39a14 alone would have in the development of
iron overload inmice having intact hepcidin regulation. To induce
iron overload, WT and Slc39a14/ mice were fed an iron-over-
loaded (FeO) diet for 4 weeks. Similar to the Hfe/;Slc39a14/
and Hfe2/;Slc39a14/ mice, Slc39a14/ mice fed the FeO
diet (Slc39a14/-FeO mice) displayed a marked impairment in
iron accumulation in the liver and increased iron loading in the
pancreas, heart, kidney, and spleen (Figure 5A). Yet, unlike in
the genetic models of iron overload, Slc39a14/-FeO mice
did accumulate a moderate amount of iron in the liver. However,
Perls’ stain of liver tissue sections from Slc39a14/-FeO mice
revealed a markedly altered cellular distribution of iron. In WT-
FeOmice, iron predominantly accumulated in periportal hepato-
cytes (Figures 5B and 5C), whereas in Slc39a14/-FeO mice,Figure 3. Ablation of Slc39a14 in the Hfe2–/– Mouse Model of Juvenile
(A) Tissue nonheme iron concentrations in WT, Slc39a14/, Hfe2/, and Hfe2
(B) Iron absorption (% of dose) was measured after intragastric gavage of 59Fe (
(C–E) Hepatic, pancreatic, and splenic 59Fe accumulation (percent of absorbed
(F–H) Representative images of Perls’ iron stain in paraffin-embedded liver section
by using standard Perls’ iron stain (blue stain) and hematoxylin counterstain. Scale
DAB-enhanced Perls’ stain (black stain) and neutral red counterstain. Arrows ind
(I–L) Plasma iron indices. (I) Plasma iron concentrations (n = 4–6 per group). (J) T
(n = 4–6 per group). (L) Plasma NTBI concentrations (n = 5–9 per group).
(M) Body weights of mice at 6 weeks of age (n = 7–11 per group). All data are show
(p < 0.05). See also Figures S1–S3 and S5 and Table S1.iron was found throughout the liver in nonparenchymal cells
(Figures 5B and 5C), including Kupffer cells (Figure S3B). Magni-
fication of a portal region from Slc39a14/ mice revealed no
detectable iron in hepatocytes (Figure 5C), even by using the
highly sensitive DAB-enhanced Perls’ stain (Figure 5D). DAB-
enhanced Perls’ stain of pancreas sections from Slc39a14/-
FeO mice revealed a pattern of iron deposition similar to that
seen in Hfe2/;Slc39a14/ mice, i.e., iron staining in inter-
and perilobular regions (Figure S4B). Plasma iron and NTBI con-
centrations did not differ among groups (Figures 5E and 5H), but
transferrin saturations were higher in Slc39a14/-FeO mice
(Figure 5G), mainly because of lower TIBC (Figure 5F). Body
weights of Slc39a14/-FeO mice were lower than those of
WT-FeO mice or Slc39a14/-FeC mice (Figure 5I).Loss of Slc39a14 and Hepcidin Expression
Because the loss of Slc39a14 impairs/alters hepatic iron accu-
mulation in the three models of iron overload used in this study,
we next asked whether these alterations would have an effect
on hepatic expression of hepcidin, the iron-regulatory hormone
produced mainly by the liver. We also measured hepatic mRNA
levels of BMP6, a key endogenous regulator of hepcidin expres-
sion that is induced by hepatic iron loading (Kautz et al., 2008).
Collectively, no differences in hepcidin mRNA levels were
observed inSlc39a14/mice compared to their respective con-
trols (Figures 6A–6C). Interestingly, however, BMP6 levels were
elevated in iron-loaded Slc39a14/ mice across all models
used in the current study (Figures 6A–6C), despite these animals
having markedly lower hepatic iron concentrations compared
to their respective controls. For example, Hfe2/ and Hfe2/;
Slc39a14/ mice had similarly elevated BMP6 mRNA levels
(i.e., 2.5-fold higher than WT or Slc39a14/ mice) (Figure 6B),
yet Hfe2/;Slc39a14/ mice had hepatic iron concentrations
that were 12-fold lower than those inHfe2/mice (i.e., 99 versus
1,292 mg Fe/g liver, Figure 3A). In Slc39a14/-FeOmice, BMP6
mRNA levels were higher than those in WT-FeOmice (Figure 6C)
despite these animals having 70% less iron in the liver (Figure 5A).
Although BMP6 is known to upregulate hepcidin expression,
higher levels of BMP6 mRNA in Slc39a14/-FeO mice
compared with WT-FeO mice were not associated with further
increases in hepcidin expression (Figure 6C). We initially thought
that this result could be confounded by anemia, which we unex-
pectedly documented in a repeat study that we performed to
obtain hemoglobin levels in the Slc39a14/-FeO mice (Fig-
ure S5F). Anemia and associated stress erythropoiesis are
known to cause the release of erythroid factors such as erythro-
ferrone that suppress hepcidin expression (Kautz et al., 2014).Hemochromatosis Prevents Hepatic Iron Overload
/;Slc39a14/ mice at 6 weeks of age (n = 4–11 per group).
n = 4–10 per group).
59Fe) was measured after intragastric gavage of 59Fe (n = 4–11 per group).
s of mice at 6 weeks of age (n = 3 per group). (F andG) Liver sections processed
bars, 200 and 100 mm, respectively. (H) Serial liver sections processed by using
icate iron deposits in nonparenchymal cells. Scale bars, 100 mm.
otal iron-binding capacity, TIBC (n = 4–6 per group). (K) Transferrin saturation
n as the mean ± SEM. Means without a common superscript differ significantly
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AB
Figure 4. Hfe2–/–;Slc39a14–/– Mice Display
Altered Iron Loading in the Pancreas
(A) Representative images of DAB-enhanced Perls’
iron stain in paraffin-embedded pancreas sections of
WT, Slc39a14/, Hfe2/, and Hfe2/;Slc39a14/
mice at 6 weeks of age (n = 4 per group). Serial sec-
tions of pancreas processed in parallel by using DAB-
enhanced Perls’ iron stain (black stain) with or without
neutral red counterstain (+NR and –NR, respectively).
Black arrowheads indicate pancreatic islets. Arrows
indicate iron deposits in Hfe2//Slc39a14/ mice.
Scale bar, 200 mm.
(B) Higher magnification of the boxed regions indi-
cated in the Hfe2/;Slc39a14/ sections in (A) and
representative images of serial sections fromHfe2/;
Slc39a14/ mice showing immunostaining for
markers of ductal epithelium (PCK-26), blood
vessel endothelium (CD-31), lymphatic endothelium
(LYVE-1), and connective tissue (collagen I), respec-
tively (n = 4 per group). Slides processed for immu-
nostaining were counterstained with hematoxylin.
Arrows indicate iron deposits; arrowheads indicate
areas of positive immunostaining (brown stain). Scale
bar, 100 mm. See also Figure S4.However, in a 3-day iron overload feeding study, which did not
affect hemoglobin levels in the Slc39a14/ mice, we again
found elevated levels of BMP6 mRNA that were not associated
with further increases in hepcidin expression (Figure S6). Our ob-
servations are similar to a dietary iron overload study in mice
showing that increased BMP6 mRNA levels higher than 2-fold
baseline are not associated with further increases in hepcidin
mRNA (Corradini et al., 2011). Collectively, these observations
suggest that BMP6 regulation of hepcidin expression becomes
saturated at relatively low BMP6 expression levels. Neverthe-
less, additional studies are needed to determine if the unex-
pected hepcidin response in anemic Slc39a14/-FeO mice is
associated with erythropoiesis-driven factors that repress he-
patic hepcidin production.
Loss of Slc39a14 Alters Splenic Iron Accumulation
The accumulation of iron in the spleen in Hfe2/;Slc39a14/
mice (Figure 3A) was unexpected as these animals also ex-
pressed very low levels of hepcidin similar to Hfe2/mice (Fig-
ure 6B). Low hepcidin expression in Hfe2/ mice is normally
associated with decreased splenic iron concentrations, as
observed in the present study (Figure 3A) and by others (Huang
et al., 2005; Niederkofler et al., 2005). The lower splenic iron con-
centrations in Hfe2/ mice are thought to arise from impaired
hepcidin expression, which in turn fails to downregulate FPN
expression in red pulp macrophages involved in recycling iron
from senescent red blood cells. The elevated FPN levels and
the resulting enhanced iron export in splenic macrophages144 Cell Metabolism 22, 138–150, July 7, 2015 ª2015 Elsevier Inc.therefore cause splenic iron levels to
decrease. Our observation of splenic iron
loading along with low hepcidin expression
in Hfe2/;Slc39a14/ mice prompted us
to examine the pattern of iron deposition
and FPN expression in the spleen. Perls’staining of spleen sections from Hfe2/;Slc39a14/ mice re-
vealed that iron accumulated in F4/80-positive macrophages
of the red pulp (Figure S5A), with iron loading in cells expressing
FPN (Figure S5B). One possible explanation for this observation
is that when iron uptake by the liver and pancreas are impaired in
iron-loaded Hfe2/;Slc39a14/ mice, NTBI in plasma is taken
up by SLC39A14-independent mechanisms in splenic macro-
phages at a rate that exceeds the capacity of FPN to export
the accumulated iron. Given that plasma NTBI concentrations
did not differ between Hfe2/ and Hfe2/;Slc39a14/ mice,
it is also possible that the chemical composition of NTBI in
Hfe2/;Slc39a14/mice is different, favoring macrophage up-
take. Selective uptake of different chemical forms of NTBI has
been postulated to contribute to the different tissue iron loading
patterns observed in various iron overload disorders (Arezes
et al., 2013). More likely, however, the iron accumulation in red
pulp macrophages of Hfe2/;Slc39a14/ mice is probably
related to hemolysis, as suggested by lower hemoglobin levels,
fewer total RBCs, normal MCV, and increased reticulocyte
counts (Figure S5E; Table S1). Indeed, hemolysis may also be
contributing to the anemia (Figure S5F; Table S2) and pro-
nounced splenic iron accumulation in Slc39a14/ mice sub-
jected to dietary iron overload (Figures 5A and S5C).
DISCUSSION
In diseases of iron overload, the liver is the primary organ that ac-
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Figure 5. Slc39a14–/– Mice Display Altered Hepatic Iron Loading in Response to Dietary Iron Overload
(A) Tissue nonheme iron concentrations in weanling WT and Slc39a14/ mice fed a normal-iron control diet (WT-FeC and Slc39a14/-FeC) or an iron-over-
loaded diet (WT-FeO andSlc39a14/-FeO) for 4 weeks (n = 6–10 per group). (B–D) Representative images of Perls’ iron stain in paraffin-embedded liver sections
of mice at 7 weeks of age (n = 3–4 per group). Branches of the portal (P) and central (C) veins are indicated.
(B and C) Liver sections processed by using standard Perls’ iron stain (blue stain) and hematoxylin counterstain. Scale bars, 200 mm and 100 mm, respectively.
(D) Serial liver sections processed by using DAB-enhanced Perls’ stain (black stain) and neutral red counterstain. Arrows indicate iron deposits in non-
parenchymal cells. Scale bar, 100 mm.
(E–H) Plasma iron indices. (E) Plasma iron concentrations (n = 6–11 per group). (F) Total iron-binding capacity, TIBC (n = 6–11 per group). (G) Transferrin saturation
(n = 6–11 per group). (H) Plasma NTBI concentrations (n = 5–6 per group).
(I) Body weights of mice at the end of the 4 week feeding study (n = 11–16 per group). All data are shown as the mean ± SEM. Means without a common
superscript differ significantly (p < 0.001). See also Figures S4 and S5.




Figure 6. Hepatic Expression of Hamp and Bmp6 mRNA in Slc39a14–/– Mice with Genetic or Dietary Iron Overload
(A–C) Relative expression of hepcidin (Hamp) and Bmp6mRNA was measured in (A) WT, Slc39a14/, Hfe/, and Hfe/;Slc39a14/mice at 4 weeks of age
(n = 7–9 per group); (B)WT, Slc39a14/,Hfe2/, andHfe2/;Slc39a14/mice at 6 weeks of age (n = 4–10 per group); and (C)WT-FeC, Slc39a14/-FeC,WT-
FeO and Slc39a14/-FeOmice at 7 weeks of age (n = 6 per group). Transcript levels were normalized to those ofRpl13a. All data are shown as themean ± SEM.
Means without a common superscript differ significantly (p < 0.01).
(D) Proposed role of SLC39A14 in iron loading of the liver and pancreas and effect of SLC39A14 deficiency on hepatic BMP6 regulation. In iron overload, the iron-
binding capacity of plasma transferrin (gray ovals) becomes exceeded, giving rise to NTBI, which loads into hepatocytes and pancreatic acinar cells via
SLC39A14. In iron overload with SLC39A14 deficiency, iron does not load in hepatocytes or acinar cells but can accumulate in nonparenchymal cells of the liver
(endothelial cells [ECs], hepatic stellate cells [HSCs], and Kupffer cells [KCs]) and collagen fibers in the pancreas. That hepatic BMP6 expression can be up-
regulated in iron overload with SLC39A14 deficiency (A–C) suggests that BMP6 expression is regulated by SLC39A14-independent iron loading of non-
parenchymal cells. See also Figure S6.cirrhosis, and hepatocellular carcinoma (Pietrangelo, 2010). Yet,
how the liver loads iron is largely unknown (Andrews, 2008;
Wang and Knutson, 2013). Our present studies using double
knockout Hfe/;Slc39a14/ and Hfe2/;Slc39a14/ mice
reveal that Slc39a14 is required for the development of hepatic
iron overload in hereditary hemochromatosis. This is observed
for both male and female mice, which are known to vary in iron
status (Figures S1A and S1B). Furthermore, the observation
that Slc39a14/mice displayed amarked impairment in the up-
take of NTBI but not of TBI supports the hypothesis that NTBI is
the main contributor to hepatic iron loading in iron overload dis-
orders (Brissot et al., 2012).
Consistent with the double knockout mice, Slc39a14/ mice
subjected to dietary iron overload did not accumulate iron in he-146 Cell Metabolism 22, 138–150, July 7, 2015 ª2015 Elsevier Inc.patocytes; however, they did accumulate iron in hepatic macro-
phages (Kupffer cells), likely because these animals upregulated
the expression of hepcidin, which blocks macrophage iron
release (Knutson et al., 2005). Collectively, our genetic and die-
tary models of iron overload indicate that SLC39A14 is required
for hepatocyte iron loading. Our data from Hfe2/;Slc39a14/
mice and dietary-iron-loaded Slc39a14/ mice further suggest
that SLC39A14 is required for iron loading of pancreatic acinar
cells, the cell type of the pancreas that preferentially loads iron
in hereditary hemochromatosis (Lesbordes-Brion et al., 2006;
Nick et al., 2009).
Although SLC39A14 appears to be the main pathway for NTBI
uptake by the liver and pancreas, our data indicate that
SLC39A14 is dispensable for NTBI uptake and iron loading of
the heart. Cardiac iron accumulation can lead to iron-overload
cardiomyopathy, estimated to account for one-third of deaths
in hemochromatosis patients (Kremastinos and Farmakis,
2011). Our NTBI injection experiments indicate that the heart
normally takes up very little plasma NTBI—in fact about 100
times less than the liver and 10 times less than the pancreas.
These relative differences in NTBI uptake likely account for the
observation that cardiac iron loading is usually a late manifesta-
tion of iron overload, occurring after the liver and pancreas
become loaded with iron (Noetzli et al., 2009; Subramaniam
et al., 2012). The finding that SLC39A14 is dispensable for car-
diac NTBI uptake may be because SLC39A14 protein levels
are markedly lower in the heart than in the pancreas or liver
(Nam et al., 2013). Possible alternative NTBI transporters in the
heart include L-type Ca2+ channels (Oudit et al., 2006), T-type
Ca2+ channels (Kumfu et al., 2011), or SLC39A8, which is closely
related to SLC39A14 (Wang et al., 2012).
Based on the data presented here, we propose the following
model for NTBI uptake and tissue iron loading in hereditary
hemochromatosis. In hemochromatosis, hepcidin levels are
abnormally low, resulting in increased iron release from reticulo-
endothelial macrophages and increased intestinal iron absorp-
tion. The increased iron release into the circulation causes
transferrin saturations to be high or fully saturated; therefore,
most of the iron absorbed by the intestine or released from
splenic macrophages will enter the portal circulation as NTBI.
The liver efficiently takes up NTBI from portal blood via
SLC39A14 located on the sinusoidal membrane of hepatocytes
(Nam et al., 2013) (Figure 6D). SLC39A14-mediated NTBI uptake
by hepatocytes largely explains why the liver is the first and fore-
most organ that accumulates iron in hereditary hemochromato-
sis. NTBI not taken up by the liver is subsequently taken up
mostly by SLC39A14 expressed by pancreatic acinar cells (Fig-
ure 6D), and to a lesser extent by SLC39A14-independent NTBI
transporters in the heart and other tissues. In hemochromatotic
mice lacking SLC39A14, NTBI in portal blood bypasses the liver
and is taken up mainly by the kidney, after being filtered through
the glomeruli and reabsorbed in the proximal tubule by luminal
transporters such as DMT1 or SLC39A8 (Canonne-Hergaux
and Gros, 2002; Fujishiro et al., 2012).
The observation that hepatic hepcidin mRNA expression was
unaffected by the loss of Slc39a14, either in single- or double-
knockout mice, indicates that the markedly altered tissue distri-
bution of iron in Slc39a14/ mice does not arise because of
altered expression of hepcidin, themaster hormone that controls
whole-body iron balance (Ganz and Nemeth, 2011). Our data
additionally show that hepatic hepcidin mRNA, produced pre-
dominantly by hepatocytes, can be induced in the absence of
detectable hepatocyte iron loading. Inmice, hepcidin expression
requires BMP6, a cytokine that triggers the BMP6/SMAD4-
signaling pathway, ultimately activating hepcidin transcription
(Andriopoulos et al., 2009; Meynard et al., 2009). Iron loading
of the liver induces the expression of BMP6 (Kautz et al.,
2008), which increases the expression of hepcidin. Although
the hepatic cell type that increases BMP6 expression in
response to iron loading remains unresolved, studies of isolated
liver cells suggest that nonparenchymal cells (Kupffer cells, stel-
late cells, and sinusoidal endothelial cells) are the main source
(Enns et al., 2013; Feng et al., 2012). Our data support thisview in that upregulated BMP6 mRNA levels in iron-loaded
Slc39a14/ mice were associated with iron loading in nonpar-
enchymal cells but not hepatocytes (Figure 6D).
In contrast to the dramatic alterations in iron metabolism
observed in Slc39a14/ mice with iron overload, only minor
perturbations in iron metabolism were observed in normal
Slc39a14/ mice (i.e., single mutant Slc39a14/ mice
consuming diets with normal amounts of iron). One consistent
finding was that liver nonheme iron concentrations were 35%
lower in young Slc39a14/ mice compared with WT animals.
This differencewas observed at 4, 6, and 7weeks of age (Figures
2A, 3A, and 5A, respectively). By 12–16 weeks, however, liver
nonheme iron concentrations did not differ between groups (Fig-
ures S1D and S1E). We originally reported that liver iron levels
were unaffected in normal Slc39a14/ mice (Hojyo et al.,
2011), but these data were from pool of mice of various ages
(4, 8, and 16 weeks), as we later noted (Nam et al., 2013). A
recent study reported that Slc39a14/ mice had liver nonheme
iron concentrations that were50% higher thanWTmice (Beker
Aydemir et al., 2012), but the age of the mice was not specified
(only a range of 8–16 weeks was noted), and iron metabolism
was not examined in the context of iron overload.
In conclusion, we identify SLC39A14 as the major route for
NTBI uptake into hepatocytes and pancreatic acinar cells in
iron overload and show that SLC39A14 is essential for iron
loading of the liver in hereditary hemochromatosis. Our data
raise the possibility that inhibitors of SLC39A14 activity or
expression could be used to prevent hepatic iron loading in
iron overload diseases, including transfusion-dependent thalas-
semia major, for which there is no cure at the present time. Such
a strategy, however, would need to be used in conjunction with
iron chelators that bind and remove NTBI from the plasma to pre-
vent it from depositing in extrahepatic tissues.EXPERIMENTAL PROCEDURES
Animals and Diets
Slc39a14+/ mice were originally on a mixed 129+Ter/SvJcl x C57BL/6 back-
ground (Hojyo et al., 2011). For tissue NTBI and TBI uptakemeasurements and
the feeding study, Slc39a14/ mice and wild-type (WT) control littermates
were on a mixed 129+Ter/SvJcl 3 C57BL/6 3 Balb/cJ background. For
studies with double knockout mice, Slc39a14+/ mice were intercrossed
with Hfe+/ mice (Levy et al., 1999) or Hfe2+/ mice (JAX Mice) on a 129S6/
SvEvTac background to generate homozygous double knockout mice along
with single mutant and WT littermate controls. Mice were genotyped at wean-
ing by extracting genomic DNA from tail snip samples followed by PCR anal-
ysis. Mice were weaned at 3 weeks of age, maintained on a standard diet
(Teklad 7912, Harlan Laboratories) containing 240 ppm iron, and housed in a
12 hr light-dark cycle. In the feeding study, mice were fed modified AIN-93G
rodent diet formulated to contain 50 ppm iron (iron control, FeC; Harlan Labo-
ratories, diet TD.130018) or 10,000 ppm (1%) carbonyl iron (iron overloaded,
FeO; Harlan Laboratories, diet TD.130015) for 4 weeks. Mice in all studies
were of mixed sex unless otherwise noted. The numbers of male and female
mice used in all experiments are outlined in Tables S3 and S4. Animal proto-
cols were approved by the Institutional Animal Care and Use Committee at
the University of Florida.
Measurement of In Vivo Tissue NTBI and TBI Uptake
Tissue NTBI uptake was measured after intravenous administration of radiola-
beled iron (Craven et al., 1987). Six-week-old mice were injected via tail vein
with 70 mg ferric citrate in 0.1 ml of 0.1M citric acid buffer (pH 6.6) to transiently
saturate plasma transferrin. Ten minutes later, 59Fe-labeled ferric-citrateCell Metabolism 22, 138–150, July 7, 2015 ª2015 Elsevier Inc. 147
(2 mCi) was administered via tail vein. Mice were sacrificed 2 hr later, and
whole-body and tissue 59Fe-associated radioactivity (counts per min, cpm)
were determined by using a WIZARD2 gamma counter (PerkinElmer). For tis-
sue TBI uptake (Wang and Knutson, 2013), mice were injected via tail vein with
150 mg 59Fe-labeled transferrin (2 mCi). Two hours later, animals were sacri-
ficed and whole-body and tissue radioactivity were determined by gamma
counting. NTBI and TBI uptakes were calculated as a percentage of whole-
body cpm.
Primary Hepatocyte Isolation and Hepatocyte NTBI Uptake
Primary hepatocytes were isolated from 13-week-old mice by collagenase
perfusion as detailed in Supplemental Information. Cellular uptake of NTBI
(59Fe-labeled ferric citrate) was measured as described previously (Wang
et al., 2012) and as detailed in Supplemental Information.
Measurement of Iron Absorption
Iron absorption was determined by 59Fe gavage (Ajioka et al., 2002). Five-
week-old mice were fasted overnight and then gavaged with 0.2 ml 59Fe-
labeled iron solution containing 2.5 mCi 59Fe-HCl, 0.5 M ascorbic acid,
0.15 M NaCl, and FeSO4 for a final total of 5 mg Fe. After gavage, mice were
returned to their cages, provided with water, fasted for 7 hr, and then provided
with food overnight. Approximately 24 hr after gavage, mice were sacrificed
and dissected. The gastrointestinal (GI) tract was removed, and major organs
and carcass were analyzed for radioactivity by gamma counting. Percentage
iron absorption was calculated as (absorbed cpm/cpm of iron administered
by gavage) 3 100. Iron accumulation in various organs after 59Fe gavage
was calculated as organ cpm / absorbed cpm 3 100. Absorbed cpm refers
to the radioactivity in the whole body (determined by the sum of major organs
and carcass cpm) without the GI tract.
Iron Status Parameters
Plasma iron, total iron-binding capacity, transferrin saturation, and tissue
nonheme iron concentrations were determined as described previously
(Wang and Knutson, 2013). Plasma NTBI was measured by using a colori-
metric method (Gosriwatana et al., 1999). The distribution of storage iron in de-
paraffinized formalin-fixed tissues sections was visualized by using Perls’
Prussian blue stain or diaminobenzidine (DAB)-enhanced Perls’ stain contain-
ing cobalt chloride, which further enhances sensitivity and produces a black
reaction product providing more contrast (Adams, 1981) as detailed in Supple-
mental Information. Slides were counterstained with 1% neutral red solution or
hematoxylin QS (Vector Labs) and visualized with an Olympus IX70 inverted
microscope and QImaging QCapture Pro 6.0 Software.
Immunoblot Analyses
Immunoblot analyses and sample preparation are detailed in Supplemental
Information.
Immunohistochemistry
For immunohistochemical analysis, paraffin-embedded pancreas sections
(except those for LYVE-1) were processed for antigen retrieval in sodium cit-
rate buffer (pH 6.0). Slides were incubated for 30 min with primary antibody
against PCK-26 (1:500; Abcam, ab6401), CD-31 (1:50; Abcam, ab28364),
LYVE-1 (1:50; Abcam; ab14917), or collagen-I (1:100; NB600-408, Novus Bio-
logicals). After incubation with species-specific biotinylated secondary anti-
bodies (1:200) for 30 min and streptavidin-HRP for 30 min (Vectastain, ABC
kit; Vector Labs), the immunoperoxidase reaction was visualized by using
the VECTOR NovaRED Peroxidase HRP Substrate Kit (Vector Labs). Slides
were counterstained with hematoxylin QS and visualized with an Olympus
IX70 inverted microscope and QImaging QCapture Pro 6.0 Software.
RNA Extraction and Quantitative Reverse-Transcriptase PCR
Total RNAwas isolated from liver samples by using RNAzol RT reagent (Molec-
ular Research Center). First-strand cDNA synthesis was performed by using
the High Capacity cDNA Reverse Transcriptase Kit (Applied Biosystems).
PCR reactions were carried out by using the Power SYBR Green PCR kit
(Applied Biosystems) on the ABI 7300 Real-Time PCR system (Applied Bio-
systems). Gene-specific primers used for PCR are listed in Supplemental
Information.148 Cell Metabolism 22, 138–150, July 7, 2015 ª2015 Elsevier Inc.Statistical Analyses
All data are shown as themean ± SEM.Means were compared by using, where
appropriate, Student’s unpaired t test or one-way ANOVA with Tukey’s post-
hoc test. A p value <0.05 was considered statistically significant. Data sets
with unequal variances were log transformed prior to statistical analysis.
Analyses were performed by using PRISM software (GraphPad).
SUPPLEMENTAL INFORMATION
Supplemental Information includes six figures, four tables, and Supplemental
Experimental Procedures and can be found with this article at http://dx.doi.
org/10.1016/j.cmet.2015.05.002.
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